Scarica l'app Stockscreener
350.95
0.32%
1.13
Dopo l'orario di chiusura:
350.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to unlock new upside? - AD HOC NEWS
Amgen And Zai Lab Trial Tests DLL3 Combo As Valuation Looks Undemanding - Yahoo Finance
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to sustain long-term growth? - AD HOC NEWS
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive new upside? - AD HOC NEWS
Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story - simplywall.st
Assetmark Inc. Increases Stake in Amgen Inc. - National Today
Assetmark Inc. Buys 14,341 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
AMGN Maintained by UBS -- Price Target Raised to $400 - GuruFocus
Morgan Stanley Raises Amgen (AMGN) Target Ahead of Q1, Truist Lifts Outlook on Pipeline Strength - Insider Monkey
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
‘Community Day Presented by Amgen’ Mobilizes Volunteers to Touch Up Greater Los Angeles Ahead of FIFA World Cup 2026 - Amgen
Beat the Market the Zacks Way: FirstEnergy, Seanergy Maritime, Amgen in Focus - TradingView — Track All Markets
HBW Advisory Services LLC Has $2.07 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Settles Denosumab Biosimilar Lawsuits with Henlius and Organon - National Today
Amgen and BeOne Medicines get Chinese approval for small cell lung cancer drug - Mugglehead Investment Magazine
Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $527.74 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Robeco Institutional Asset Management B.V. Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KG&L Capital Management LLC - MarketBeat
Curtis Advisory Group Adds Amgen Shares to Portfolio - National Today
Factory Mutual Insurance Trims Amgen Stake - National Today
Clarity Wealth Advisors LLC Invests $3.91 Million in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Is It Time To Revisit Amgen (AMGN) After The Recent 4.6% Share Price Pullback - simplywall.st
AVALON CAPITAL MANAGEMENT's Amgen Inc(AMGN) Holding History - GuruFocus
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer | PharmExec - Pharmaceutical Executive
Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors - TipRanks
Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB) - simplywall.st
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again - Yahoo! Finance Canada
OFI Invest Asset Management Boosts Amgen Stock Position - National Today
Amgen’s lung cancer drug tarlatamab wins China approval - WTAQ
Amgen (NASDAQ:AMGN) Price Target Raised to $326.00 - MarketBeat
Amgen’s Tarlatamab Approved in China - Pharmaceutical Executive
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
OFI Invest Asset Management Increases Stake in Amgen - National Today
OFI Invest Asset Management Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN - MarketBeat
Encompass Wealth Advisors Trims Amgen Stake by Over 50% - National Today
Amgen's lung cancer drug tarlatamab wins China approval - Reuters
Encompass Wealth Advisors LLC Sells 3,010 Shares of Amgen Inc. $AMGN - MarketBeat
8,657 Shares in Amgen Inc. $AMGN Purchased by Flagship Capital Management Inc. - MarketBeat
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
What Amgen (AMGN)'s TEPEZZA On‑Body Injector Phase 3 Results Mean For Shareholders - simplywall.st
Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Guggenheim Adjusts Amgen (AMGN) Price Target to $351, Maintains - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $351.00 - MarketBeat
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know - MSN
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Guggenheim Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $351 - Moomoo
Guggenheim raises Amgen stock price target to $351 on product mix - Investing.com Canada
Amgen (AMGN) Stock: GLP-1 Drug MariTide Drives Analyst Optimism - CoinCentral
We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. - Barron's
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $350 - Moomoo
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
Truist raises Amgen stock price target to $325 on revenue outlook - Investing.com
Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat - simplywall.st
3.53%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):